Reference on copy number variations in pleomorphic xanthoastrocytoma: Implications for diagnostic approach.

7/10 signature Amplification CDKN2A/B CNV Classification Copy Number Variations EGFR Homozygous deletion Methylation PXA Pleomorphic Xanthoastrocytoma

Journal

Free neuropathology
ISSN: 2699-4445
Titre abrégé: Free Neuropathol
Pays: Germany
ID NLM: 101768755

Informations de publication

Date de publication:
Jan 2023
Historique:
received: 19 10 2023
accepted: 30 10 2023
medline: 29 11 2023
pubmed: 29 11 2023
entrez: 29 11 2023
Statut: epublish

Résumé

Pleomorphic xanthoastrocytoma (PXA) poses a diagnostic challenge. The present study relies on methylation-based predictions and focuses on copy number variations (CNV) in PXA. We identified 551 tumors from patients having received the histologic diagnosis or differential diagnosis pleomorphic xanthoastrocytoma (PXA) uploaded to the web page www.molecularneuropathology.org. Of these 551 tumors, 165 received the prediction "methylation class (anaplastic) pleomorphic xanthoastrocytoma" with a calibrated score >=0.9 by the brain tumor classifier version v12.8 and, therefore, were defined the PXA reference set designated mcPXAref. In addition to these 165 mcPXAref, 767 other tumors received the prediction mcPXA with a calibrated score >=0.9 but without a histological PXA diagnosis. The total number of individual tumors predicted by histology and/or by methylome based classification as PXA, mcPXA or both was 1318, and these were designated the study cohort. The selection of a control cohort was guided by methylation-based predictions recurrently observed for the other 386/551 tumors diagnosed as histologic PXA. 131/386 received predictions for another entity besides PXA with a score >=0.9. Control tumors corresponding to the 11 most common other predictions were selected, adding up to 1100 reference cases. CNV profiles were calculated from all methylation datasets of the study and control cohorts. Special attention was given to the 7/10 signature, gene amplifications and homozygous deletion of CDKN2A/B. Comparison of CNV in the subsets of the study cohort and the control cohort were used to establish relations independent of histological diagnoses. Tumors in mcPXA were highly homogenous in regard to CNV alterations, irrespective of the histological diagnoses. The 7/10 signature commonly present in glioblastoma, IDH-wildtype, was present in 15-20% of mcPXA, whereas amplification of oncogenes (likewise common in glioblastoma) was very rare in mcPXA (<1%). In contrast, the histology-based PXA group exhibited high variance in regard to methylation classes as well as to CNVs. Our data add to the notion, that histologically defined PXA likely only represent a subset of the biological disease.

Identifiants

pubmed: 38026572
doi: 10.17879/freeneuropathology-2023-5156
pmc: PMC10646999
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Cancer. 1999 May 1;85(9):2033-45
pubmed: 10223246
Cancer Sci. 2019 Feb;110(2):828-832
pubmed: 30609203
Brain Pathol. 2018 Mar;28(2):172-182
pubmed: 28181325
Acta Neuropathol Commun. 2022 Jan 10;10(1):5
pubmed: 35012690
Nature. 2018 Mar 22;555(7697):469-474
pubmed: 29539639
Oncogene. 2007 Feb 15;26(7):1088-97
pubmed: 16909113
Cancer. 1979 Nov;44(5):1839-52
pubmed: 498051
Brain Pathol. 2019 Jan;29(1):85-96
pubmed: 30051528
Acta Neuropathol. 2018 Nov;136(5):793-803
pubmed: 30187121

Auteurs

David E Reuss (DE)

Department of Neuropathology, Institute of Pathology, University of Heidelberg, Heidelberg, Germany.
Clinical Cooperation Unit Neuropathology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.

Daniel Schrimpf (D)

Department of Neuropathology, Institute of Pathology, University of Heidelberg, Heidelberg, Germany.
Clinical Cooperation Unit Neuropathology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.

Damian Stichel (D)

Department of Neuropathology, Institute of Pathology, University of Heidelberg, Heidelberg, Germany.
Clinical Cooperation Unit Neuropathology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.

Azadeh Ebrahimi (A)

Department of Neuropathology, DGNN Brain Tumor Reference Center, University of Bonn, Bonn, Germany.

Chris Dampier (C)

Laboratory of Pathology, National Cancer Institute, Centre for Cancer Research, Bethesda, MD, USA.

Kenneth Aldape (K)

Laboratory of Pathology, National Cancer Institute, Centre for Cancer Research, Bethesda, MD, USA.

Matija Snuderl (M)

Department of Pathology, New York University Langone Health and School of Medicine, New York, New York, USA.

David Capper (D)

Department of Neuropathology, Charité - Universitätsmedizin Berlin, Berlin, Germany; German Cancer Consortium (DKTK), Berlin, Germany; German Cancer Research Center (DKFZ), Heidelberg, Germany.

Martin Sill (M)

Division of Pediatric Neurooncology, German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany.
Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.

David T W Jones (DTW)

Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.
Pediatric Glioma Research Group, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Stefan M Pfister (SM)

Clinical Cooperation Unit Neuropathology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.
Department of Pediatric Oncology, Hematology and Immunology, Heidelberg University Hospital, Heidelberg, Germany.

Felix Sahm (F)

Department of Neuropathology, Institute of Pathology, University of Heidelberg, Heidelberg, Germany.
Clinical Cooperation Unit Neuropathology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.

Andreas von Deimling (A)

Department of Neuropathology, Institute of Pathology, University of Heidelberg, Heidelberg, Germany.
Clinical Cooperation Unit Neuropathology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.

Classifications MeSH